Clinical Trial Update: Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating palbociclib plus letrozole as a second-line treatment after progression on chemotherapy in ER/PR-positive ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Letrozole (letrozole)
• Palbociclib (palbociclib)

Snippet

Sponsor: Latin American Cooperative Oncology Group | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED